865088-75-1

Upstream product

• 675-20-7 piperidin-2-one 
• 192702-01-5 3-chloro-4-fluorobenzyl bromide 
• 670-98-4 methyl benzenesulfinate 

Downstream Products

• 865088-66-0 C₁₃H₁₂ClFN₂O 
• 865088-36-4 2-(3-chloro-4-fluorobenzyl)-8-hydroxy-6-cyclopropyl-2,3,4,4a,5,6-hexahydro-2,6-naphthyridine-1,7-dione 
• 865088-68-2 C₁₃H₁₅ClFNO₂ 
• 865088-67-1 C₁₄H₁₅ClFNO₃ 
• 865088-69-3 C₁₄H₁₇ClFNO₄S 
• 865088-70-6 C₁₆H₂₀ClFN₂O 
• 865088-72-8 C₁₉H₂₂ClFN₂O₄ 
• 1080623-44-4 methanesulfonic acid (R)-4-{[6-(3-chloro-4-fluorobenzyl)-3-methanesulfonyloxy-4-methoxy-5-oxo-5,6,7,8-tetrahydro-2,6-naphthyridine-1-carbonyl]-methyl-amino}-2,2-dimethyl-3-(tetrahydropyran-2-yloxy)-butyl ester 
• 1019339-37-7 6-(3-chloro-4-fluorobenzyl)-N-[(2R)-4-hydroxy-3,3-dimethyl-2-(tetrahydro-2H-pyran-2-yloxy)butyl]-4-methoxy-N-methyl-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide 
• 1019339-38-8 (4R)-11-(3-chloro-4-fluorobenzyl)-9-methoxy-2,5,5-trimethyl-4-((tetrahydro-2H-pyran-2-yl)oxy)-3,4,5,6,12,13-hexahydro-2H-[1,4]diazocino[2,1-a][2,6]naphthyridine-1,8,10(11H)-trione 
• 915065-47-3 N-[2-(benzyloxy)ethyl]-N-(4-methanesulfonyloxybutyl)-6-(3-chloro-4-fluorobenzyl)-4-methoxy-3,5-dioxo-2,3,5,6,7,8-hexahydro-2,6-naphthyridine-1-carboxamide 
• 915065-52-0 11-(3-chloro-4-fluorobenzyl)-9-methoxy-2-(2-morpholin-4-ylethyl)-3,4,5,6,12,13-hexahydro-2H[1,4]diazocino[2,1-a]-2,6-naphthyridine-1,8,10(11H)-trione 

Relevant academic research and scientific papers

HIV INTEGRASE INHIBITORS

Stereoisomers of compounds of Formula I are disclosed: wherein V1,V2, R5a, R5b, R5c, R8 and R9b are defined herein and wherein the stereoisomer contains 2 chiral centers in the 8-membered ring and one of the chiral centers is due to the presence of a chiral ring carbon. The isomers are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Crystalline forms of an HIV integrase inhibitor

Crystalline forms of a hexahydro-diazocinonaphthyridine trione compound are disclosed. The compound and its crystalline forms thereof are HIV integrase inhibitors useful for the prophylaxis or treatment of HIV infection or for the prophylaxis, treatment or delay in the onset or progression of AIDS.

HIV INTEGRASE INHIBITORS

Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, Rl, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

HIV INTEGRASE INHIBITORS

Hydroxy (tetra- or hexa-)hydronaphthyridine dione compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication wherein X1, X2, R4 and R5 are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.